Yazen is a Swedish digital obesity clinic that has done something no other European weight loss company reviewed here has managed: presented outcome data on more than 30,000 treated patients at the European Congress on Obesity. Reporting 16.6% weight loss at 18 months alongside 70% treatment adherence, across a real-world population rather than a trial cohort, places Yazen in a different evidentiary category from the marketing statistics that dominate this market. This review evaluates Yazen across its clinical model, evidence, programme content, and European positioning.

Quick Takeaway:

• Swedish digital clinic treating obesity as a chronic, treatable condition
• Presented data on over 30,000 patients at the European Congress on Obesity (ECO) 2025 in Málaga
• Reported 16.6% weight loss at 18 months with 70% treatment adherence
• Combines medication with diet, exercise, and mental health support in a single app
• Each patient has a YazenCoach and a treatment team accessible directly through the app

Looking for a Better Alternative?

Yazen has the strongest published real-world evidence of any European provider reviewed here. We nonetheless benchmark every provider against the highest-rated service we track: CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy overall, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

CoreAge Rx serves patients in the United States. Yazen's own market is Sweden; the closest comparisons elsewhere in Europe are Embla, Second Nature, and Oviva.

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. Available to patients in the United States.

What Is Yazen?

Yazen is a Swedish digital healthcare service for weight loss, combining medication, diet, exercise, and mental health support. Its clinical framing is explicit and unusually clear: obesity is a chronic condition that can be treated, not a failure of willpower, and patients who have struggled with weight their whole lives can be helped with the right treatment and guidance.

That framing matters clinically. Treating obesity as a chronic disease implies long-term management rather than a course of treatment with an end date — which is exactly what the evidence on weight regain after GLP-1 discontinuation supports.

Yazen operates through an app in which each patient has their own YazenCoach and treatment team. Patients track progress, message their team, and receive personalised guidance, with the clinical and behavioural elements delivered together rather than as separate products.

The Evidence

This is what distinguishes Yazen, and it deserves to be set out precisely.

At the European Congress on Obesity 2025 in Málaga, Yazen presented data from more than 30,000 treated patients reporting 16.6% weight loss at 18 months and 70% treatment adherence. Its published descriptive analysis notes these results were achieved alongside improvements in metabolic health markers including laboratory values, despite limited medication availability during the period and without use of the maximum recommended dose.

Three things make this notable:

1. Scale. Thirty thousand patients is an order of magnitude beyond the sample sizes behind most provider claims.
2. Adherence. Seventy percent adherence is far above typical real-world GLP-1 persistence, which is frequently reported below 50% at one year. Adherence is the variable that most determines whether treatment works outside a trial.
3. Dose. Achieving 16.6% without maximum dosing suggests the behavioural and coaching wrapper is doing meaningful work, not just the drug.

Yazen has separately reported that 10,000 patients collectively lost 100 tonnes of weight, and describes reduced healthcare costs as a consequence.

Important: This remains company-generated observational data presented at a conference, not an independent randomised controlled trial. Observational programme data cannot establish causation and is subject to selection effects — patients who stay enrolled are not the same as patients who leave. It is nonetheless a far higher standard of evidence than the industry norm.

How Yazen Works

1. Assessment with a doctor. Clinical evaluation of suitability for treatment.
2. Treatment team and coach. You are assigned a YazenCoach and treatment team within the app.
3. Medication where appropriate. Prescribed and managed by the clinical team.
4. Integrated programme. Diet, exercise, and mental health support delivered alongside medication.
5. Ongoing management. Progress tracking, team messaging, and personalised advice through the app.

Pricing and Access

Yazen publishes its pricing on its Swedish site, and pricing structures for Swedish digital healthcare differ substantially from UK and US private models — Swedish patients may access parts of digital care within regional healthcare frameworks depending on the service and region.

Because pricing and reimbursement in Nordic healthcare differ meaningfully from the UK and US markets covered elsewhere on this site, we do not quote figures that may not apply to your situation. Check Yazen's published pricing page for current rates.

Learn About Yazen

Swedish digital weight loss clinic combining medication, diet, exercise, and mental health support with a personal coach and treatment team.

Eligibility, Providers, and Clinical Requirements

Yazen operates as a Swedish healthcare provider, with clinical assessment by doctors and treatment governed by Swedish medical regulation. Standard obesity treatment criteria apply, with clinical judgement about medication suitability.

Its emphasis on metabolic health markers rather than weight alone is clinically appropriate. Improvements in HbA1c, lipids, and blood pressure are the outcomes that actually change long-term health, and Yazen's published analysis reports improvements across these alongside weight change.

Medication and Fulfilment

Medication is prescribed by Yazen's clinical team under Swedish prescribing arrangements. Yazen's published analysis notes results were achieved despite limited medication availability during the study period — a reference to the European GLP-1 supply constraints of 2023–2025 — and without use of the maximum recommended dose.

Ongoing Support, Nutrition, and Coaching

Yazen's programme is integrated by design:

• Personal YazenCoach for each patient
• Treatment team accessible directly in the app
• Diet guidance as a core component
• Exercise programming
• Mental health support, which almost no private weight loss provider includes
• Progress tracking and personalised advice
• Long-term chronic condition framing rather than a fixed-length course

The inclusion of mental health support alongside medication is genuinely differentiating. Emotional eating, disordered eating patterns, and the psychological impact of long-term weight struggle are clinically significant and largely unaddressed in the private GLP-1 market.

Pros and Cons

Pros

• Strongest published real-world dataset of any European provider reviewed here
• 30,000+ patients presented at a major scientific congress
• 70% adherence, far above typical real-world GLP-1 persistence
• Mental health support integrated into the programme
• Explicit chronic disease framing supporting long-term management
• Results reported alongside metabolic health markers, not weight alone

Cons

• Operates in the Swedish market, limiting access for other European patients
• Evidence is observational company data, not an independent randomised trial
• Pricing structures differ from UK and US models and require direct verification
• Selection effects mean reported outcomes reflect patients who stayed enrolled
• Service and language primarily Swedish

Best Use Cases and Limitations

Best for: Swedish patients seeking evidence-informed digital obesity treatment with integrated psychological support and a long-term management approach.

Limitations: Patients outside Sweden, and anyone requiring independent randomised evidence rather than observational programme data.

Alternatives to Yazen

Frequently Asked Questions

What outcomes has Yazen published?

At the European Congress on Obesity 2025 in Málaga, Yazen presented data from over 30,000 treated patients showing 16.6% weight loss at 18 months and 70% treatment adherence, alongside improvements in metabolic health markers including laboratory values.

Is Yazen's evidence from a clinical trial?

No. It is real-world observational data from Yazen's own treated patient population, presented at a scientific congress and published as a descriptive analysis. That is a considerably higher standard than typical provider marketing, but it cannot establish causation the way a randomised controlled trial can.

Why is 70% adherence significant?

Real-world persistence on GLP-1 therapy is frequently reported below 50% at one year. Adherence is the single biggest determinant of whether treatment produces results outside a trial setting, so a 70% figure — if representative — suggests the programme is keeping patients on treatment substantially better than the norm.

Does Yazen include mental health support?

Yes. Yazen combines medication with support for diet, exercise, and mental health, which is unusual among private weight loss providers.

Where does Yazen operate?

Yazen is a Swedish digital healthcare service. Its programme, pricing, and clinical arrangements are structured for the Swedish market.

Did Yazen achieve these results at maximum medication doses?

No. Yazen's published analysis states the results were achieved despite limited medication availability and without use of the maximum recommended dose, which suggests the coaching and behavioural components contributed meaningfully.

Bottom Line

Yazen is the most evidentially serious digital obesity clinic covered on this site. Presenting real-world data on 30,000 patients at a major scientific congress — and reporting adherence rates alongside weight outcomes — reflects a company measuring the things that actually matter.

Strengths: exceptional published dataset, high reported adherence, integrated mental health support, chronic disease framing, metabolic markers reported alongside weight.

Drawbacks: Swedish market only, observational rather than randomised evidence, subject to selection effects, and pricing that requires direct verification.

Best for: Swedish patients wanting evidence-informed, long-term obesity treatment.

Skip if: you are outside Sweden or need randomised trial evidence.

Adherence is the number to watch when comparing any weight loss programme. A treatment producing 16% loss in the 70% of patients who stay on it will outperform one producing 20% in the 40% who do.

US readers: CoreAge Rx offers all-in monthly pricing from $179–$399 including medication and provider messaging, with 12–24 hour approvals. Save up to $200 on your first three months.

Medical disclaimer: Informational only, not medical advice. GLP-1 receptor agonists are prescription medicines with real risks and contraindications. Consult a qualified healthcare professional before starting or changing treatment. Availability and pricing vary by country.

Sources: Yazen published programme, pricing, and news pages including its ECO 2025 data presentation and descriptive analysis of the Yazen model; European Association for the Study of Obesity congress information; European Medicines Agency medicine information.

Date reviewed: August 2026